Mangoceuticals (MGRX) said late Monday it "strongly refutes" Eli Lilly's (LLY) claims that the company "improperly" imitated its weight-loss Zepbound and Mounjaro medicines.
"MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide," the company added.
Eli Lilly filed lawsuits against medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its weight-loss drug Zepbound.
Eli Lilly did not immediately respond to MT Newswires' request for comment.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。